1-4 of 4
alefacept
Close
Sort by
Journal Articles

LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia

Ramon V. Tiu, MD, Valeria Visconte, PhD, Paul Elson, Michael J. Clemente, Ali Tabarroki, MD, Edy Hasrouni, Amy Porter, Lindsey Mooney, Manuel G. Afable, II, Ricki Englehaupt, Joy Juersivich, RN, MSc, Kathleen Cooper, RN, MSc, Mikkael A. Sekeres, MD, MS, Yogen Saunthararajah, M.D., Jaroslaw P. Maciejewski, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3711.
https://doi.org/10.1182/blood.V122.21.3711.3711
Published: 2013
Journal Articles

Towards Clinically Feasible Co-Stimulatory Blockade for Tolerance Induction: Transient Treatment with CTLA4-Ig, Anti-CD48 and FTY720 Enables Durable Engraftment of T Cell Depleted BM Allografts Following Non-Myeloablative Conditioning.

Esther Bachar-Lustig, PhD, Dalit Tchorsh-Yutsis, PhD, Eran Ophir, MSc, Yael Zlotnikov Klionsky, MSc, Noga Or-Geva, BSc, Yair Reisner, PhD
Journal: Blood
Blood (2010) 116 (21): 3726.
https://doi.org/10.1182/blood.V116.21.3726.3726
Published: 2010
Journal Articles

Alefacept Treatment for Graft Vs. Host Disease May Not Suppress the Graft Vs. Leukemia Effect.

Liliane Dray, Aliza Matusevich, Igor Resnick, Memet Aker, M.D, Polina Stepansky, Reuven Or, Michael Y. Shapira, MD
Journal: Blood
Blood (2009) 114 (22): 2223.
https://doi.org/10.1182/blood.V114.22.2223.2223
Published: 2009
Journal Articles

Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept

Christy J. Stotler, Bijan Eghtesad, Eric Hsi, Bernard Silver
Journal: Blood
Blood (2009) 113 (21): 5365–5366.
https://doi.org/10.1182/blood-2009-02-207431
Published: 2009